Institutional Sign In

Go

Novartis Czech Republic - EBIT Growth

Novartis Czech Republic`s EBIT Growth reached -25.0 % in 2017. This is 175 % less than in the previous year.

$1.99

Buy EBIT Growth data for Novartis Czech Republic.

$19.99

Buy all data for Novartis Czech Republic.

from $199/month

Buy annual subscriptions for all our products.

 
Company Unit 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Amgen Czech Republic % ... ... ... ... ...           56.9 -37.9 11.3 34.9 -15.5    
Bayer Czech Republic % ... ... ...               6.82 -34.6 22.5 8.75 17.7    
GlaxoSmithKline Czech Republic % ... ... ...               31.9 -25.9 -21.8 -29.3 6.70    
Merck Czech Republic % ... ...                 182 25.3 -41.6 9.10 80.1    
Novartis Czech Republic %                     1.78 12.9 -2.41 56.3 13.5    
Pfizer Czech Republic % ... ...                 114 -79.1 169 -0.115 -42.2    
Roche Czech Republic % ... ... ...               -39.8 -16.9 165 -26.8 -39.3   ...
Sanofi-Aventis Czech Republic % ... ... ... ...             29.9 -13.9 25.2 -88.8 796    
Servier Czech Republic % ... ... ... ... ... ... ... ... ... ... ... ... 4.17 0.879 11.5    
Walmark % ... ... ...               34.0 -77.4 -40.2 207 -413